schliessen

Filtern

 

Bibliotheken

Global economic burden of Chagas disease: a computational simulation model

Summary Background As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers. We developed a Markov simulation model to estima... Full description

Journal Title: The Lancet infectious diseases 2013, Vol.13 (4), p.342-348
Main Author: Lee, Bruce Y, Dr
Other Authors: Bacon, Kristina M, MPH , Bottazzi, Maria Elena, PhD , Hotez, Peter J, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: London: Elsevier Ltd
ID: ISSN: 1473-3099
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3763184
title: Global economic burden of Chagas disease: a computational simulation model
format: Article
creator:
  • Lee, Bruce Y, Dr
  • Bacon, Kristina M, MPH
  • Bottazzi, Maria Elena, PhD
  • Hotez, Peter J, MD
subjects:
  • Absenteeism
  • Acute Disease
  • Analysis
  • Article
  • Biological and medical sciences
  • Chagas Cardiomyopathy - economics
  • Chagas Cardiomyopathy - epidemiology
  • Chagas Disease - economics
  • Chagas Disease - epidemiology
  • Chagas Disease - mortality
  • Chagas' disease
  • Chronic Disease
  • Computer Simulation
  • Computer-generated environments
  • Cost of Illness
  • Disabled Persons - statistics & numerical data
  • Economic aspects
  • Efficiency
  • Europe - epidemiology
  • Global Health
  • Health Care Costs - statistics & numerical data
  • Heart Failure - parasitology
  • Human protozoal diseases
  • Humans
  • Hypertrophy - parasitology
  • Infectious Disease
  • Infectious diseases
  • Latin America - epidemiology
  • Markov Chains
  • Medical sciences
  • Parasitic diseases
  • Protozoal diseases
  • Public health
  • Quality-Adjusted Life Years
  • South America - epidemiology
  • Trypanosomiasis
  • United States - epidemiology
  • Viscera - parasitology
  • Viscera - pathology
ispartof: The Lancet infectious diseases, 2013, Vol.13 (4), p.342-348
description: Summary Background As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers. We developed a Markov simulation model to estimate the global and regional health and economic burden of Chagas disease from the societal perspective. Methods Our Markov model structure had a 1 year cycle length and consisted of five states: acute disease, indeterminate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death. Major model parameter inputs, including the annual probabilities of transitioning from one state to another, and present case estimates for Chagas disease came from various sources, including WHO and other epidemiological and disease-surveillance-based reports. We calculated annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions. We used a discount rate of 3% to adjust all costs and DALYs to present-day values. Findings On average, an infected individual incurs US$474 in health-care costs and 0·51 DALYs annually. Over his or her lifetime, an infected individual accrues an average net present value of $3456 and 3·57 DALYs. Globally, the annual burden is $627·46 million in health-care costs and 806 170 DALYs. The global net present value of currently infected individuals is $24·73 billion in health-care costs and 29 385 250 DALYs. Conversion of this burden into costs results in annual per-person costs of $4660 and lifetime per-person costs of $27 684. Global costs are $7·19 billion per year and $188·80 billion per lifetime. More than 10% of these costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic. A substantial proportion of the burden emerges from lost productivity from cardiovascular disease-induced early mortality. Interpretation The economic burden of Chagas disease is similar to or exceeds those of other prominent diseases globally (eg, rotavirus $2·0 billion, cervical cancer $4·7 billion) even in the USA (Lyme disease $2·5 billion), where Chagas disease has not been traditionally endemic, suggesting an economic argument for more attention and efforts towards control of Chagas disease. Funding Bill & Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1473-3099
fulltext: fulltext
issn:
  • 1473-3099
  • 1474-4457
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7843752
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3763184
sourceformatXML
sourcesystemPC
galeidA339284672
sourcerecordidA339284672
originalsourceidFETCH-LOGICAL-1846t-aca42c62fba3b0741740831bfd2b4b083fb0d8d1585ded08e750f08a9df21a2b3
addsrcrecordideNqFkm1r1TAYhosobk5_glIQYYJn5q1NozAZQzdl4Af1c8jLk7PMNjk27WD_3vT0uJ0zhFFok_R67tzJcxfFS4yOMML1-x-YcbqgSIhDTN9yhBBZ4EfFfl5mC8Yq_ng9npG94llKVwhhjhF7WuwRSkVFWLNffDtro1ZtCSaG2HlT6rG3EMroytNLtVSptD6BSvChVKWJ3Woc1OBjyCXJd2O7npRdtNA-L5441SZ4sfkeFL--fP55er64-H729fTkYoEbVg8LZRQjpiZOK6oRZ5gz1FCsnSWa6Tx0GtnG4qqpLFjUAK-QQ40S1hGsiKYHxfGsuxp1B9ZAGHrVylXvO9XfyKi83P0T_KVcxmtJeU2zhyxwPgvEFQTle9iptQEGGa0kNZcgHLiGaSFqoxAzTSMcxTXR2TzPZ8hShxsvffwzQhpk55OBtlUB4pgkpgRzQQSnGX19D72KY58vcqKwqISomi1qqVqQPriYj2AmUXmSm0byFfJp26P_UPmxkHsYAzif13cK3m0V6DH5ACm_kl9eDmmpxpR28WrGTR9T6sHd3hBGcoqfXMdPTtnK7uU6fnlwULzabs1t1b-8ZeDNBlDJqNb1Khif7ri8dwYn7uM9A8bPwcsH9e2DNj7N1ZBjeO2hl8l4CAZsbrYZpI3-QYXjewqm9cFny7_hBtJd52QiEs0ikwamawVM_wI1Ahul
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1319599583
display
typearticle
titleGlobal economic burden of Chagas disease: a computational simulation model
sourceAlma/SFX Local Collection
creatorLee, Bruce Y, Dr ; Bacon, Kristina M, MPH ; Bottazzi, Maria Elena, PhD ; Hotez, Peter J, MD
creatorcontribLee, Bruce Y, Dr ; Bacon, Kristina M, MPH ; Bottazzi, Maria Elena, PhD ; Hotez, Peter J, MD
descriptionSummary Background As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers. We developed a Markov simulation model to estimate the global and regional health and economic burden of Chagas disease from the societal perspective. Methods Our Markov model structure had a 1 year cycle length and consisted of five states: acute disease, indeterminate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death. Major model parameter inputs, including the annual probabilities of transitioning from one state to another, and present case estimates for Chagas disease came from various sources, including WHO and other epidemiological and disease-surveillance-based reports. We calculated annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions. We used a discount rate of 3% to adjust all costs and DALYs to present-day values. Findings On average, an infected individual incurs US$474 in health-care costs and 0·51 DALYs annually. Over his or her lifetime, an infected individual accrues an average net present value of $3456 and 3·57 DALYs. Globally, the annual burden is $627·46 million in health-care costs and 806 170 DALYs. The global net present value of currently infected individuals is $24·73 billion in health-care costs and 29 385 250 DALYs. Conversion of this burden into costs results in annual per-person costs of $4660 and lifetime per-person costs of $27 684. Global costs are $7·19 billion per year and $188·80 billion per lifetime. More than 10% of these costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic. A substantial proportion of the burden emerges from lost productivity from cardiovascular disease-induced early mortality. Interpretation The economic burden of Chagas disease is similar to or exceeds those of other prominent diseases globally (eg, rotavirus $2·0 billion, cervical cancer $4·7 billion) even in the USA (Lyme disease $2·5 billion), where Chagas disease has not been traditionally endemic, suggesting an economic argument for more attention and efforts towards control of Chagas disease. Funding Bill & Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study.
identifier
0ISSN: 1473-3099
1EISSN: 1474-4457
2DOI: 10.1016/S1473-3099(13)70002-1
3PMID: 23395248
4CODEN: LANCAO
languageeng
publisherLondon: Elsevier Ltd
subjectAbsenteeism ; Acute Disease ; Analysis ; Article ; Biological and medical sciences ; Chagas Cardiomyopathy - economics ; Chagas Cardiomyopathy - epidemiology ; Chagas Disease - economics ; Chagas Disease - epidemiology ; Chagas Disease - mortality ; Chagas' disease ; Chronic Disease ; Computer Simulation ; Computer-generated environments ; Cost of Illness ; Disabled Persons - statistics & numerical data ; Economic aspects ; Efficiency ; Europe - epidemiology ; Global Health ; Health Care Costs - statistics & numerical data ; Heart Failure - parasitology ; Human protozoal diseases ; Humans ; Hypertrophy - parasitology ; Infectious Disease ; Infectious diseases ; Latin America - epidemiology ; Markov Chains ; Medical sciences ; Parasitic diseases ; Protozoal diseases ; Public health ; Quality-Adjusted Life Years ; South America - epidemiology ; Trypanosomiasis ; United States - epidemiology ; Viscera - parasitology ; Viscera - pathology
ispartofThe Lancet infectious diseases, 2013, Vol.13 (4), p.342-348
rights
0Elsevier Ltd
12013 Elsevier Ltd
22014 INIST-CNRS
3Copyright © 2013 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2013 Elsevier B.V.
5Copyright Elsevier Limited Apr 2013
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1846t-aca42c62fba3b0741740831bfd2b4b083fb0d8d1585ded08e750f08a9df21a2b3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27239528$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23395248$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Lee, Bruce Y, Dr
1Bacon, Kristina M, MPH
2Bottazzi, Maria Elena, PhD
3Hotez, Peter J, MD
title
0Global economic burden of Chagas disease: a computational simulation model
1The Lancet infectious diseases
addtitleLancet Infect Dis
descriptionSummary Background As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers. We developed a Markov simulation model to estimate the global and regional health and economic burden of Chagas disease from the societal perspective. Methods Our Markov model structure had a 1 year cycle length and consisted of five states: acute disease, indeterminate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death. Major model parameter inputs, including the annual probabilities of transitioning from one state to another, and present case estimates for Chagas disease came from various sources, including WHO and other epidemiological and disease-surveillance-based reports. We calculated annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions. We used a discount rate of 3% to adjust all costs and DALYs to present-day values. Findings On average, an infected individual incurs US$474 in health-care costs and 0·51 DALYs annually. Over his or her lifetime, an infected individual accrues an average net present value of $3456 and 3·57 DALYs. Globally, the annual burden is $627·46 million in health-care costs and 806 170 DALYs. The global net present value of currently infected individuals is $24·73 billion in health-care costs and 29 385 250 DALYs. Conversion of this burden into costs results in annual per-person costs of $4660 and lifetime per-person costs of $27 684. Global costs are $7·19 billion per year and $188·80 billion per lifetime. More than 10% of these costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic. A substantial proportion of the burden emerges from lost productivity from cardiovascular disease-induced early mortality. Interpretation The economic burden of Chagas disease is similar to or exceeds those of other prominent diseases globally (eg, rotavirus $2·0 billion, cervical cancer $4·7 billion) even in the USA (Lyme disease $2·5 billion), where Chagas disease has not been traditionally endemic, suggesting an economic argument for more attention and efforts towards control of Chagas disease. Funding Bill & Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study.
subject
0Absenteeism
1Acute Disease
2Analysis
3Article
4Biological and medical sciences
5Chagas Cardiomyopathy - economics
6Chagas Cardiomyopathy - epidemiology
7Chagas Disease - economics
8Chagas Disease - epidemiology
9Chagas Disease - mortality
10Chagas' disease
11Chronic Disease
12Computer Simulation
13Computer-generated environments
14Cost of Illness
15Disabled Persons - statistics & numerical data
16Economic aspects
17Efficiency
18Europe - epidemiology
19Global Health
20Health Care Costs - statistics & numerical data
21Heart Failure - parasitology
22Human protozoal diseases
23Humans
24Hypertrophy - parasitology
25Infectious Disease
26Infectious diseases
27Latin America - epidemiology
28Markov Chains
29Medical sciences
30Parasitic diseases
31Protozoal diseases
32Public health
33Quality-Adjusted Life Years
34South America - epidemiology
35Trypanosomiasis
36United States - epidemiology
37Viscera - parasitology
38Viscera - pathology
issn
01473-3099
11474-4457
fulltexttrue
rsrctypearticle
creationdate2013
recordtypearticle
recordideNqFkm1r1TAYhosobk5_glIQYYJn5q1NozAZQzdl4Af1c8jLk7PMNjk27WD_3vT0uJ0zhFFok_R67tzJcxfFS4yOMML1-x-YcbqgSIhDTN9yhBBZ4EfFfl5mC8Yq_ng9npG94llKVwhhjhF7WuwRSkVFWLNffDtro1ZtCSaG2HlT6rG3EMroytNLtVSptD6BSvChVKWJ3Woc1OBjyCXJd2O7npRdtNA-L5441SZ4sfkeFL--fP55er64-H729fTkYoEbVg8LZRQjpiZOK6oRZ5gz1FCsnSWa6Tx0GtnG4qqpLFjUAK-QQ40S1hGsiKYHxfGsuxp1B9ZAGHrVylXvO9XfyKi83P0T_KVcxmtJeU2zhyxwPgvEFQTle9iptQEGGa0kNZcgHLiGaSFqoxAzTSMcxTXR2TzPZ8hShxsvffwzQhpk55OBtlUB4pgkpgRzQQSnGX19D72KY58vcqKwqISomi1qqVqQPriYj2AmUXmSm0byFfJp26P_UPmxkHsYAzif13cK3m0V6DH5ACm_kl9eDmmpxpR28WrGTR9T6sHd3hBGcoqfXMdPTtnK7uU6fnlwULzabs1t1b-8ZeDNBlDJqNb1Khif7ri8dwYn7uM9A8bPwcsH9e2DNj7N1ZBjeO2hl8l4CAZsbrYZpI3-QYXjewqm9cFny7_hBtJd52QiEs0ikwamawVM_wI1Ahul
startdate2013
enddate2013
creator
0Lee, Bruce Y, Dr
1Bacon, Kristina M, MPH
2Bottazzi, Maria Elena, PhD
3Hotez, Peter J, MD
general
0Elsevier Ltd
1Lancet Publishing Group
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TZ
113V.
127QL
137RV
147U9
157X7
167XB
1788E
188AO
198C1
208C2
218FI
228FJ
238FK
24ABUWG
25BENPR
26C1K
27FYUFA
28GHDGH
29H94
30K9.
31KB0
32M0S
33M1P
34M7N
35NAPCQ
36PQEST
37PQQKQ
38PQUKI
397X8
40BOBZL
41CLFQK
425PM
sort
creationdate2013
titleGlobal economic burden of Chagas disease: a computational simulation model
authorLee, Bruce Y, Dr ; Bacon, Kristina M, MPH ; Bottazzi, Maria Elena, PhD ; Hotez, Peter J, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1846t-aca42c62fba3b0741740831bfd2b4b083fb0d8d1585ded08e750f08a9df21a2b3
rsrctypearticles
prefilterarticles
languageeng
creationdate2013
topic
0Absenteeism
1Acute Disease
2Analysis
3Article
4Biological and medical sciences
5Chagas Cardiomyopathy - economics
6Chagas Cardiomyopathy - epidemiology
7Chagas Disease - economics
8Chagas Disease - epidemiology
9Chagas Disease - mortality
10Chagas' disease
11Chronic Disease
12Computer Simulation
13Computer-generated environments
14Cost of Illness
15Disabled Persons - statistics & numerical data
16Economic aspects
17Efficiency
18Europe - epidemiology
19Global Health
20Health Care Costs - statistics & numerical data
21Heart Failure - parasitology
22Human protozoal diseases
23Humans
24Hypertrophy - parasitology
25Infectious Disease
26Infectious diseases
27Latin America - epidemiology
28Markov Chains
29Medical sciences
30Parasitic diseases
31Protozoal diseases
32Public health
33Quality-Adjusted Life Years
34South America - epidemiology
35Trypanosomiasis
36United States - epidemiology
37Viscera - parasitology
38Viscera - pathology
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Lee, Bruce Y, Dr
1Bacon, Kristina M, MPH
2Bottazzi, Maria Elena, PhD
3Hotez, Peter J, MD
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9Pharma and Biotech Premium PRO
10ProQuest Central (Corporate)
11Bacteriology Abstracts (Microbiology B)
12Nursing & Allied Health Database
13Virology and AIDS Abstracts
14Health & Medical Collection
15ProQuest Central (purchase pre-March 2016)
16Medical Database (Alumni Edition)
17ProQuest Pharma Collection
18Public Health Database
19Lancet Titles
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23ProQuest Central (Alumni Edition)
24ProQuest Central
25Environmental Sciences and Pollution Management
26Health Research Premium Collection
27Health Research Premium Collection (Alumni)
28AIDS and Cancer Research Abstracts
29ProQuest Health & Medical Complete (Alumni)
30Nursing & Allied Health Database (Alumni Edition)
31Health & Medical Collection (Alumni Edition)
32Medical Database
33Algology Mycology and Protozoology Abstracts (Microbiology C)
34Nursing & Allied Health Premium
35ProQuest One Academic Eastern Edition
36ProQuest One Academic
37ProQuest One Academic UKI Edition
38MEDLINE - Academic
39OpenAIRE (Open Access)
40OpenAIRE
41PubMed Central (Full Participant titles)
jtitleThe Lancet infectious diseases
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Lee, Bruce Y, Dr
1Bacon, Kristina M, MPH
2Bottazzi, Maria Elena, PhD
3Hotez, Peter J, MD
formatjournal
genrearticle
ristypeJOUR
atitleGlobal economic burden of Chagas disease: a computational simulation model
jtitleThe Lancet infectious diseases
addtitleLancet Infect Dis
date2013
risdate2013
volume13
issue4
spage342
epage348
pages342-348
issn1473-3099
eissn1474-4457
codenLANCAO
abstractSummary Background As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers. We developed a Markov simulation model to estimate the global and regional health and economic burden of Chagas disease from the societal perspective. Methods Our Markov model structure had a 1 year cycle length and consisted of five states: acute disease, indeterminate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death. Major model parameter inputs, including the annual probabilities of transitioning from one state to another, and present case estimates for Chagas disease came from various sources, including WHO and other epidemiological and disease-surveillance-based reports. We calculated annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions. We used a discount rate of 3% to adjust all costs and DALYs to present-day values. Findings On average, an infected individual incurs US$474 in health-care costs and 0·51 DALYs annually. Over his or her lifetime, an infected individual accrues an average net present value of $3456 and 3·57 DALYs. Globally, the annual burden is $627·46 million in health-care costs and 806 170 DALYs. The global net present value of currently infected individuals is $24·73 billion in health-care costs and 29 385 250 DALYs. Conversion of this burden into costs results in annual per-person costs of $4660 and lifetime per-person costs of $27 684. Global costs are $7·19 billion per year and $188·80 billion per lifetime. More than 10% of these costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic. A substantial proportion of the burden emerges from lost productivity from cardiovascular disease-induced early mortality. Interpretation The economic burden of Chagas disease is similar to or exceeds those of other prominent diseases globally (eg, rotavirus $2·0 billion, cervical cancer $4·7 billion) even in the USA (Lyme disease $2·5 billion), where Chagas disease has not been traditionally endemic, suggesting an economic argument for more attention and efforts towards control of Chagas disease. Funding Bill & Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study.
copLondon
pubElsevier Ltd
pmid23395248
doi10.1016/S1473-3099(13)70002-1
oafree_for_read